590 related articles for article (PubMed ID: 33928898)
1. Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021.
Fabiani M; Ramigni M; Gobbetto V; Mateo-Urdiales A; Pezzotti P; Piovesan C
Euro Surveill; 2021 Apr; 26(17):. PubMed ID: 33928898
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
3. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
4. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.
Thompson MG; Burgess JL; Naleway AL; Tyner HL; Yoon SK; Meece J; Olsho LEW; Caban-Martinez AJ; Fowlkes A; Lutrick K; Kuntz JL; Dunnigan K; Odean MJ; Hegmann KT; Stefanski E; Edwards LJ; Schaefer-Solle N; Grant L; Ellingson K; Groom HC; Zunie T; Thiese MS; Ivacic L; Wesley MG; Lamberte JM; Sun X; Smith ME; Phillips AL; Groover KD; Yoo YM; Gerald J; Brown RT; Herring MK; Joseph G; Beitel S; Morrill TC; Mak J; Rivers P; Harris KM; Hunt DR; Arvay ML; Kutty P; Fry AM; Gaglani M
MMWR Morb Mortal Wkly Rep; 2021 Apr; 70(13):495-500. PubMed ID: 33793460
[TBL] [Abstract][Full Text] [Related]
5. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
6. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
Casas Fischer R
Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
[TBL] [Abstract][Full Text] [Related]
7. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.
Eyre DW; Lumley SF; Wei J; Cox S; James T; Justice A; Jesuthasan G; O'Donnell D; Howarth A; Hatch SB; Marsden BD; Jones EY; Stuart DI; Ebner D; Hoosdally S; Crook DW; Peto TEA; Walker TM; Stoesser NE; Matthews PC; Pouwels KB; Walker AS; Jeffery K
Clin Microbiol Infect; 2021 Oct; 27(10):1516.e7-1516.e14. PubMed ID: 34111577
[TBL] [Abstract][Full Text] [Related]
8. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.
Hall V; Foulkes S; Insalata F; Kirwan P; Saei A; Atti A; Wellington E; Khawam J; Munro K; Cole M; Tranquillini C; Taylor-Kerr A; Hettiarachchi N; Calbraith D; Sajedi N; Milligan I; Themistocleous Y; Corrigan D; Cromey L; Price L; Stewart S; de Lacy E; Norman C; Linley E; Otter AD; Semper A; Hewson J; D'Arcangelo S; Chand M; Brown CS; Brooks T; Islam J; Charlett A; Hopkins S;
N Engl J Med; 2022 Mar; 386(13):1207-1220. PubMed ID: 35172051
[TBL] [Abstract][Full Text] [Related]
9. Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study.
Iwamoto M; Ukimura A; Ogawa T; Kawanishi F; Osaka N; Kubota M; Mori T; Sawamura R; Nishihara M; Suzuki T; Uchiyama K
PLoS One; 2022; 17(5):e0268529. PubMed ID: 35576209
[TBL] [Abstract][Full Text] [Related]
10. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
11. Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study.
Ripabelli G; Tamburro M; Buccieri N; Adesso C; Caggiano V; Cannizzaro F; Di Palma MA; Mantuano G; Montemitro VG; Natale A; Rodio L; Sammarco ML
J Community Health; 2022 Apr; 47(2):211-225. PubMed ID: 34628568
[TBL] [Abstract][Full Text] [Related]
12. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
[TBL] [Abstract][Full Text] [Related]
14. Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization.
Bonura F; De Grazia S; Bonura C; Sanfilippo GL; Giammanco GM; Amodio E; Ferraro D
J Appl Microbiol; 2022 May; 132(5):3987-3994. PubMed ID: 35083832
[TBL] [Abstract][Full Text] [Related]
15. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
Lutrick K; Rivers P; Yoo YM; Grant L; Hollister J; Jovel K; Khan S; Lowe A; Baccam Z; Hanson H; Olsho LEW; Fowlkes A; Caban-Martinez AJ; Porter C; Yoon S; Meece J; Gaglani M; Burns J; Mayo Lamberte J; Nakayima Miiro F; Bissonnette A; LeClair L; Kutty PK; Romine JK; Stefanski E; Edwards LJ; Ellingson K; Gerald JK; Bedrick EJ; Madhivanan P; Krupp K; Gerald LB; Thompson M; Burgess JL
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1761-1765. PubMed ID: 34968373
[TBL] [Abstract][Full Text] [Related]
16. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of the Comirnaty and the Vaxzevria vaccines in preventing SARS-CoV-2 infection among residents in Lazio region (Italy).
Fano V; Crielesi A; Coviello E; Fabiani M; Salvatore Miglietta A; Colaiocco G; Moretti I; Pasqua C; Vivaldi F; De Angelis G; Cerimele M
Vaccine; 2022 Apr; 40(18):2540-2545. PubMed ID: 35341646
[TBL] [Abstract][Full Text] [Related]
18. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
[TBL] [Abstract][Full Text] [Related]
19. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
[TBL] [Abstract][Full Text] [Related]
20. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers.
Maruyama A; Sawa T; Teramukai S; Katoh N
J Infect Chemother; 2022 Jul; 28(7):934-942. PubMed ID: 35361536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
